NO312706B1 - Anvendelse av tiadiazolforbindelser til fremstilling av farmasöytiske preparater for behandling av schizofreni ogschizofreniforme sykdommer - Google Patents
Anvendelse av tiadiazolforbindelser til fremstilling av farmasöytiske preparater for behandling av schizofreni ogschizofreniforme sykdommer Download PDFInfo
- Publication number
- NO312706B1 NO312706B1 NO19960619A NO960619A NO312706B1 NO 312706 B1 NO312706 B1 NO 312706B1 NO 19960619 A NO19960619 A NO 19960619A NO 960619 A NO960619 A NO 960619A NO 312706 B1 NO312706 B1 NO 312706B1
- Authority
- NO
- Norway
- Prior art keywords
- thiadiazol
- mmol
- pyridine
- solution
- stirred
- Prior art date
Links
- 201000000980 schizophrenia Diseases 0.000 title claims abstract description 18
- 208000020186 Schizophreniform disease Diseases 0.000 title claims abstract description 7
- 238000011282 treatment Methods 0.000 title claims description 21
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
- 150000004867 thiadiazoles Chemical class 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 144
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 3
- 239000001301 oxygen Substances 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- LRTWCQHCJKYNPS-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pentylsulfanyl-1,2,5-thiadiazole Chemical compound CCCCCSC1=NSN=C1C1=CCCN(C)C1 LRTWCQHCJKYNPS-UHFFFAOYSA-N 0.000 claims 1
- VGRPVZDIAOGCMM-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-propoxy-1,2,5-thiadiazole Chemical compound CCCOC1=NSN=C1C1=CCCN(C)C1 VGRPVZDIAOGCMM-UHFFFAOYSA-N 0.000 claims 1
- MHWUWCDFTFBXNV-UHFFFAOYSA-N 3-butoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCOC1=NSN=C1C1=CCCN(C)C1 MHWUWCDFTFBXNV-UHFFFAOYSA-N 0.000 claims 1
- SFXHHGRYNXLPKT-UHFFFAOYSA-N 3-butylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCSC1=NSN=C1C1=CCCN(C)C1 SFXHHGRYNXLPKT-UHFFFAOYSA-N 0.000 claims 1
- WCJPIRVYBXBRCS-UHFFFAOYSA-N 3-ethoxy-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCOC1=NSN=C1C1=CCCNC1 WCJPIRVYBXBRCS-UHFFFAOYSA-N 0.000 claims 1
- FVFYCQYZPZLAQO-UHFFFAOYSA-N 3-ethoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCOC1=NSN=C1C1=CCCN(C)C1 FVFYCQYZPZLAQO-UHFFFAOYSA-N 0.000 claims 1
- GHXWVRUTFAIAPR-UHFFFAOYSA-N 3-ethylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCSC1=NSN=C1C1=CCCN(C)C1 GHXWVRUTFAIAPR-UHFFFAOYSA-N 0.000 claims 1
- ZJBSSLFOLFDLJC-UHFFFAOYSA-N 3-hexylsulfanyl-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCCCSC1=NSN=C1C1=CCCNC1 ZJBSSLFOLFDLJC-UHFFFAOYSA-N 0.000 claims 1
- MVFFDRHJDZRXRN-UHFFFAOYSA-N 3-methoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound COC1=NSN=C1C1=CCCN(C)C1 MVFFDRHJDZRXRN-UHFFFAOYSA-N 0.000 claims 1
- GKJOESOKTSYJRW-UHFFFAOYSA-N 3-pentylsulfanyl-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCCSC1=NSN=C1C1=CCCNC1 GKJOESOKTSYJRW-UHFFFAOYSA-N 0.000 claims 1
- DLGQCNAWPBBNHZ-UHFFFAOYSA-N S1C(=CC=C1)SCCSC1=NSN=C1C=1CN(CCC1)C Chemical compound S1C(=CC=C1)SCCSC1=NSN=C1C=1CN(CCC1)C DLGQCNAWPBBNHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 14
- 241000124008 Mammalia Species 0.000 abstract description 4
- 239000005864 Sulphur Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 201
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 180
- 239000000243 solution Substances 0.000 description 116
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 104
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 102
- 239000011541 reaction mixture Substances 0.000 description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- 239000000203 mixture Substances 0.000 description 50
- 239000012074 organic phase Substances 0.000 description 44
- CMPNWGQBNRHIQZ-UHFFFAOYSA-N 3-chloro-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound ClC1=NSN=C1C1=CC=CN=C1 CMPNWGQBNRHIQZ-UHFFFAOYSA-N 0.000 description 38
- 150000003891 oxalate salts Chemical class 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 238000004440 column chromatography Methods 0.000 description 33
- 239000003480 eluent Substances 0.000 description 33
- 238000001704 evaporation Methods 0.000 description 33
- 230000008020 evaporation Effects 0.000 description 33
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 33
- 229910000033 sodium borohydride Inorganic materials 0.000 description 32
- 239000012279 sodium borohydride Substances 0.000 description 32
- 239000012071 phase Substances 0.000 description 26
- 229910004298 SiO 2 Inorganic materials 0.000 description 25
- 238000001914 filtration Methods 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 13
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 229910052708 sodium Inorganic materials 0.000 description 13
- 239000012312 sodium hydride Substances 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 230000001143 conditioned effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000000164 antipsychotic agent Substances 0.000 description 6
- -1 pad Substances 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 5
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 208000028017 Psychotic disease Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229910052681 coesite Inorganic materials 0.000 description 5
- 229910052906 cristobalite Inorganic materials 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 229910052682 stishovite Inorganic materials 0.000 description 5
- 229910052905 tridymite Inorganic materials 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000000561 anti-psychotic effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- HSWIVDLMDNZGBB-UHFFFAOYSA-N 3-chloro-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1Cl HSWIVDLMDNZGBB-UHFFFAOYSA-N 0.000 description 3
- 208000027776 Extrapyramidal disease Diseases 0.000 description 3
- JBHUBOISLBWHAR-UHFFFAOYSA-N Flumezapine Chemical compound C1CN(C)CCN1C1=NC2=CC(F)=CC=C2NC2=C1C=C(C)S2 JBHUBOISLBWHAR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940005529 antipsychotics Drugs 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 229950005785 flumezapine Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- ZCHHRLHTBGRGOT-PLNGDYQASA-N (z)-hex-2-en-1-ol Chemical compound CCC\C=C/CO ZCHHRLHTBGRGOT-PLNGDYQASA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- CETWDUZRCINIHU-UHFFFAOYSA-N 2-heptanol Chemical compound CCCCCC(C)O CETWDUZRCINIHU-UHFFFAOYSA-N 0.000 description 2
- SPXLQIUHQCAWMY-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(3-thiophen-2-ylsulfanylpropoxy)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1OCCCSC1=CC=CS1 SPXLQIUHQCAWMY-UHFFFAOYSA-N 0.000 description 2
- QITXVJLXWISAPK-UHFFFAOYSA-M 3-(1-methylpyridin-1-ium-3-yl)-4-(6,6,6-trifluorohexoxy)-1,2,5-thiadiazole;iodide Chemical compound [I-].C[N+]1=CC=CC(C=2C(=NSN=2)OCCCCCC(F)(F)F)=C1 QITXVJLXWISAPK-UHFFFAOYSA-M 0.000 description 2
- GWJVTLJLGQRUAC-UHFFFAOYSA-M 3-(1-methylpyridin-1-ium-3-yl)-4-methylsulfanyl-1,2,5-thiadiazole;iodide Chemical compound [I-].CSC1=NSN=C1C1=CC=C[N+](C)=C1 GWJVTLJLGQRUAC-UHFFFAOYSA-M 0.000 description 2
- GHQFJYMVRMCBKW-UHFFFAOYSA-M 3-(1-methylpyridin-1-ium-3-yl)-4-octylsulfanyl-1,2,5-thiadiazole;iodide Chemical compound [I-].CCCCCCCCSC1=NSN=C1C1=CC=C[N+](C)=C1 GHQFJYMVRMCBKW-UHFFFAOYSA-M 0.000 description 2
- IEFGKJQRJZBQPM-UHFFFAOYSA-M 3-(1-methylpyridin-1-ium-3-yl)-4-pent-4-enoxy-1,2,5-thiadiazole;iodide Chemical compound [I-].C[N+]1=CC=CC(C=2C(=NSN=2)OCCCC=C)=C1 IEFGKJQRJZBQPM-UHFFFAOYSA-M 0.000 description 2
- IIDKNKWJYSJBPG-UHFFFAOYSA-M 3-(1-methylpyridin-1-ium-3-yl)-4-pentylsulfanyl-1,2,5-thiadiazole;iodide Chemical compound [I-].CCCCCSC1=NSN=C1C1=CC=C[N+](C)=C1 IIDKNKWJYSJBPG-UHFFFAOYSA-M 0.000 description 2
- UEKVRXRQOWQKFI-UHFFFAOYSA-M 3-(1-methylpyridin-1-ium-3-yl)-4-prop-2-enoxy-1,2,5-thiadiazole;iodide Chemical compound [I-].C[N+]1=CC=CC(C=2C(=NSN=2)OCC=C)=C1 UEKVRXRQOWQKFI-UHFFFAOYSA-M 0.000 description 2
- GBBSFWMXZBFUIU-UHFFFAOYSA-M 3-(1-methylpyridin-1-ium-3-yl)-4-propoxy-1,2,5-thiadiazole;iodide Chemical compound [I-].CCCOC1=NSN=C1C1=CC=C[N+](C)=C1 GBBSFWMXZBFUIU-UHFFFAOYSA-M 0.000 description 2
- VLMZHYBFTLJUTH-UHFFFAOYSA-M 3-(1-methylpyridin-1-ium-3-yl)-4-propylsulfanyl-1,2,5-thiadiazole;iodide Chemical compound [I-].CCCSC1=NSN=C1C1=CC=C[N+](C)=C1 VLMZHYBFTLJUTH-UHFFFAOYSA-M 0.000 description 2
- AYTNXCOYUFWTEH-UHFFFAOYSA-M 3-(2-methylpropoxy)-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CC(C)COC1=NSN=C1C1=CC=C[N+](C)=C1 AYTNXCOYUFWTEH-UHFFFAOYSA-M 0.000 description 2
- WQUMWFNJJQIJRE-UHFFFAOYSA-N 3-(2-methylpropoxy)-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CC(C)COC1=NSN=C1C1=CC=CN=C1 WQUMWFNJJQIJRE-UHFFFAOYSA-N 0.000 description 2
- AALKDTPIKNIELA-UHFFFAOYSA-M 3-(3-methylbut-2-enoxy)-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CC(C)=CCOC1=NSN=C1C1=CC=C[N+](C)=C1 AALKDTPIKNIELA-UHFFFAOYSA-M 0.000 description 2
- ZDRTVGUQVJKQMU-UHFFFAOYSA-N 3-(3-methylbut-2-enoxy)-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CC(C)=CCOC1=NSN=C1C1=CC=CN=C1 ZDRTVGUQVJKQMU-UHFFFAOYSA-N 0.000 description 2
- RMYMEBGDPPJISP-UHFFFAOYSA-M 3-(3-methylbutoxy)-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CC(C)CCOC1=NSN=C1C1=CC=C[N+](C)=C1 RMYMEBGDPPJISP-UHFFFAOYSA-M 0.000 description 2
- LVOFKNONKRQOFG-UHFFFAOYSA-N 3-(3-methylbutoxy)-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CC(C)CCOC1=NSN=C1C1=CC=CN=C1 LVOFKNONKRQOFG-UHFFFAOYSA-N 0.000 description 2
- WZGYPHIXCBTMJQ-UHFFFAOYSA-N 3-(5-methylthiophen-2-yl)propan-1-ol Chemical compound CC1=CC=C(CCCO)S1 WZGYPHIXCBTMJQ-UHFFFAOYSA-N 0.000 description 2
- CYSVTYSXQBZFFF-IPZCTEOASA-M 3-[(e)-hex-2-enoxy]-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CCC\C=C\COC1=NSN=C1C1=CC=C[N+](C)=C1 CYSVTYSXQBZFFF-IPZCTEOASA-M 0.000 description 2
- QZHWHSMSPNUXGP-FXRZFVDSSA-M 3-[(e)-hex-3-enoxy]-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CC\C=C\CCOC1=NSN=C1C1=CC=C[N+](C)=C1 QZHWHSMSPNUXGP-FXRZFVDSSA-M 0.000 description 2
- CDUPVCKNZWPNSJ-ONEGZZNKSA-N 3-[(e)-hex-3-enoxy]-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CC\C=C\CCOC1=NSN=C1C1=CC=CN=C1 CDUPVCKNZWPNSJ-ONEGZZNKSA-N 0.000 description 2
- DLNKJRXKLGHFLF-UHFFFAOYSA-M 3-but-3-enoxy-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].C[N+]1=CC=CC(C=2C(=NSN=2)OCCC=C)=C1 DLNKJRXKLGHFLF-UHFFFAOYSA-M 0.000 description 2
- AFHRQUXMNBJMDV-UHFFFAOYSA-N 3-but-3-enoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound C=CCCOC1=NSN=C1C1=CC=CN=C1 AFHRQUXMNBJMDV-UHFFFAOYSA-N 0.000 description 2
- OKTWHVBSBNCONO-UHFFFAOYSA-M 3-butoxy-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CCCCOC1=NSN=C1C1=CC=C[N+](C)=C1 OKTWHVBSBNCONO-UHFFFAOYSA-M 0.000 description 2
- YHMWTFGQYMKBLO-UHFFFAOYSA-N 3-butoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCCCOC1=NSN=C1C1=CC=CN=C1 YHMWTFGQYMKBLO-UHFFFAOYSA-N 0.000 description 2
- CQLVUKUNPPAPNO-UHFFFAOYSA-M 3-butylsulfanyl-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CCCCSC1=NSN=C1C1=CC=C[N+](C)=C1 CQLVUKUNPPAPNO-UHFFFAOYSA-M 0.000 description 2
- WWRQHNYMYVIDAR-UHFFFAOYSA-N 3-butylsulfanyl-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCCCSC1=NSN=C1C1=CC=CN=C1 WWRQHNYMYVIDAR-UHFFFAOYSA-N 0.000 description 2
- PRLOGXFZQIFLAE-UHFFFAOYSA-N 3-chloro-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole;hydrochloride Chemical compound Cl.ClC1=NSN=C1C1=CCCNC1 PRLOGXFZQIFLAE-UHFFFAOYSA-N 0.000 description 2
- SKDWFKQVJIGJCO-UHFFFAOYSA-M 3-chloro-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].C[N+]1=CC=CC(C=2C(=NSN=2)Cl)=C1 SKDWFKQVJIGJCO-UHFFFAOYSA-M 0.000 description 2
- RLVYVDSZOYOCLP-UHFFFAOYSA-M 3-ethoxy-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CCOC1=NSN=C1C1=CC=C[N+](C)=C1 RLVYVDSZOYOCLP-UHFFFAOYSA-M 0.000 description 2
- GJHZFNVGXYFFAU-UHFFFAOYSA-N 3-ethoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCOC1=NSN=C1C1=CC=CN=C1 GJHZFNVGXYFFAU-UHFFFAOYSA-N 0.000 description 2
- NMWRGDAYXSINEJ-UHFFFAOYSA-M 3-ethylsulfanyl-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CCSC1=NSN=C1C1=CC=C[N+](C)=C1 NMWRGDAYXSINEJ-UHFFFAOYSA-M 0.000 description 2
- CKLZJAJZZOXDPM-UHFFFAOYSA-M 3-hex-4-enoxy-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CC=CCCCOC1=NSN=C1C1=CC=C[N+](C)=C1 CKLZJAJZZOXDPM-UHFFFAOYSA-M 0.000 description 2
- PKMWXDYEECJVPU-UHFFFAOYSA-N 3-hex-4-enoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CC=CCCCOC1=NSN=C1C1=CC=CN=C1 PKMWXDYEECJVPU-UHFFFAOYSA-N 0.000 description 2
- HQGVDHDRUUWVNY-UHFFFAOYSA-M 3-hex-5-enoxy-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].C[N+]1=CC=CC(C=2C(=NSN=2)OCCCCC=C)=C1 HQGVDHDRUUWVNY-UHFFFAOYSA-M 0.000 description 2
- WHRGYNQUJQBPER-UHFFFAOYSA-N 3-hex-5-enoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound C=CCCCCOC1=NSN=C1C1=CC=CN=C1 WHRGYNQUJQBPER-UHFFFAOYSA-N 0.000 description 2
- PLDTVIHYDHJMEQ-UHFFFAOYSA-M 3-hexoxy-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CCCCCCOC1=NSN=C1C1=CC=C[N+](C)=C1 PLDTVIHYDHJMEQ-UHFFFAOYSA-M 0.000 description 2
- VJUYUCDQCJLBOZ-UHFFFAOYSA-N 3-hexoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCCCCCOC1=NSN=C1C1=CC=CN=C1 VJUYUCDQCJLBOZ-UHFFFAOYSA-N 0.000 description 2
- CIKRGAFRQUGFJA-UHFFFAOYSA-M 3-hexylsulfanyl-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CCCCCCSC1=NSN=C1C1=CC=C[N+](C)=C1 CIKRGAFRQUGFJA-UHFFFAOYSA-M 0.000 description 2
- ZJPRZJBJWWMEAC-UHFFFAOYSA-M 3-methoxy-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].COC1=NSN=C1C1=CC=C[N+](C)=C1 ZJPRZJBJWWMEAC-UHFFFAOYSA-M 0.000 description 2
- CWBOCZDAKBHZCF-UHFFFAOYSA-N 3-methoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound COC1=NSN=C1C1=CC=CN=C1 CWBOCZDAKBHZCF-UHFFFAOYSA-N 0.000 description 2
- IWTBVKIGCDZRPL-UHFFFAOYSA-N 3-methylpentanol Chemical compound CCC(C)CCO IWTBVKIGCDZRPL-UHFFFAOYSA-N 0.000 description 2
- BHSNUVIPSNWCDP-UHFFFAOYSA-N 3-methylsulfanyl-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CSC1=NSN=C1C1=CC=CN=C1 BHSNUVIPSNWCDP-UHFFFAOYSA-N 0.000 description 2
- OLMNYOCJQLMMNM-UHFFFAOYSA-N 3-octoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCCCCCCCOC1=NSN=C1C1=CC=CN=C1 OLMNYOCJQLMMNM-UHFFFAOYSA-N 0.000 description 2
- TYJXLJSOIPXFMZ-UHFFFAOYSA-N 3-pent-4-enoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound C=CCCCOC1=NSN=C1C1=CC=CN=C1 TYJXLJSOIPXFMZ-UHFFFAOYSA-N 0.000 description 2
- SLBKDWANFYLWFZ-UHFFFAOYSA-N 3-pentoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCCCCOC1=NSN=C1C1=CC=CN=C1 SLBKDWANFYLWFZ-UHFFFAOYSA-N 0.000 description 2
- OFPSSSJDVAQRKC-UHFFFAOYSA-N 3-pentylsulfanyl-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCCCCSC1=NSN=C1C1=CC=CN=C1 OFPSSSJDVAQRKC-UHFFFAOYSA-N 0.000 description 2
- TWWBVSZKNWFUEV-UHFFFAOYSA-N 3-prop-2-enoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound C=CCOC1=NSN=C1C1=CC=CN=C1 TWWBVSZKNWFUEV-UHFFFAOYSA-N 0.000 description 2
- WQJCDIIQFMIJME-UHFFFAOYSA-N 3-propan-2-yloxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CC(C)OC1=NSN=C1C1=CC=CN=C1 WQJCDIIQFMIJME-UHFFFAOYSA-N 0.000 description 2
- VTSXYLPJMYSJEM-UHFFFAOYSA-N 3-propoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCCOC1=NSN=C1C1=CC=CN=C1 VTSXYLPJMYSJEM-UHFFFAOYSA-N 0.000 description 2
- JJXFRFDBQFOQNF-UHFFFAOYSA-N 3-propylsulfanyl-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCCSC1=NSN=C1C1=CC=CN=C1 JJXFRFDBQFOQNF-UHFFFAOYSA-N 0.000 description 2
- GGPQCBMGVJWDOK-UHFFFAOYSA-N 3-pyridin-3-yl-4-(6,6,6-trifluorohexoxy)-1,2,5-thiadiazole Chemical compound FC(F)(F)CCCCCOC1=NSN=C1C1=CC=CN=C1 GGPQCBMGVJWDOK-UHFFFAOYSA-N 0.000 description 2
- LSVRBYGDJATZKX-UHFFFAOYSA-N 6-[(4-pyridin-3-yl-1,2,5-thiadiazol-3-yl)sulfanyl]hexanenitrile Chemical compound N#CCCCCCSC1=NSN=C1C1=CC=CN=C1 LSVRBYGDJATZKX-UHFFFAOYSA-N 0.000 description 2
- INJWBNOQVNVRFR-UHFFFAOYSA-M 6-[[4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]hexanenitrile;iodide Chemical compound [I-].C[N+]1=CC=CC(C=2C(=NSN=2)SCCCCCC#N)=C1 INJWBNOQVNVRFR-UHFFFAOYSA-M 0.000 description 2
- 206010001540 Akathisia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RZKSECIXORKHQS-UHFFFAOYSA-N Heptan-3-ol Chemical compound CCCCC(O)CC RZKSECIXORKHQS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- VTIODUHBZHNXFP-UHFFFAOYSA-N hex-4-en-1-ol Chemical compound CC=CCCCO VTIODUHBZHNXFP-UHFFFAOYSA-N 0.000 description 2
- UIZVMOZAXAMASY-UHFFFAOYSA-N hex-5-en-1-ol Chemical compound OCCCCC=C UIZVMOZAXAMASY-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- QNVRIHYSUZMSGM-UHFFFAOYSA-N hexan-2-ol Chemical compound CCCCC(C)O QNVRIHYSUZMSGM-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- NMRPBPVERJPACX-UHFFFAOYSA-N octan-3-ol Chemical compound CCCCCC(O)CC NMRPBPVERJPACX-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- 239000001618 (3R)-3-methylpentan-1-ol Substances 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- ZCHHRLHTBGRGOT-SNAWJCMRSA-N (E)-hex-2-en-1-ol Chemical compound CCC\C=C\CO ZCHHRLHTBGRGOT-SNAWJCMRSA-N 0.000 description 1
- UFLHIIWVXFIJGU-ONEGZZNKSA-N (E)-hex-3-en-1-ol Chemical compound CC\C=C\CCO UFLHIIWVXFIJGU-ONEGZZNKSA-N 0.000 description 1
- FJMWICTXKAHSOH-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(3-methylpentoxy)-1,2,5-thiadiazole Chemical compound OC(=O)\C=C\C(O)=O.CCC(C)CCOC1=NSN=C1C1=CCCN(C)C1 FJMWICTXKAHSOH-WLHGVMLRSA-N 0.000 description 1
- LZPRADBZGXGPBY-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-heptan-3-yloxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound OC(=O)\C=C\C(O)=O.CCCCC(CC)OC1=NSN=C1C1=CCCN(C)C1 LZPRADBZGXGPBY-WLHGVMLRSA-N 0.000 description 1
- HATFCWMKGPPSFJ-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-hexan-2-yloxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound OC(=O)\C=C\C(O)=O.CCCCC(C)OC1=NSN=C1C1=CCCN(C)C1 HATFCWMKGPPSFJ-WLHGVMLRSA-N 0.000 description 1
- BXPGLGSMFAWAHJ-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-hexan-3-yloxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound OC(=O)\C=C\C(O)=O.CCCC(CC)OC1=NSN=C1C1=CCCN(C)C1 BXPGLGSMFAWAHJ-WLHGVMLRSA-N 0.000 description 1
- KVUVVWQFGVSAKA-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(4-methylpentoxy)-1,2,5-thiadiazole Chemical compound OC(=O)\C=C/C(O)=O.CC(C)CCCOC1=NSN=C1C1=CCCN(C)C1 KVUVVWQFGVSAKA-BTJKTKAUSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
- VMKOFRJSULQZRM-UHFFFAOYSA-N 1-bromooctane Chemical compound CCCCCCCCBr VMKOFRJSULQZRM-UHFFFAOYSA-N 0.000 description 1
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
- UCPZTWDNVJKOEQ-UHFFFAOYSA-N 1-methyl-3,6-dihydro-2H-pyridine oxalic acid Chemical compound OC(=O)C(O)=O.CN1CCC=CC1 UCPZTWDNVJKOEQ-UHFFFAOYSA-N 0.000 description 1
- HLNJFEXZDGURGZ-UHFFFAOYSA-M 1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1 HLNJFEXZDGURGZ-UHFFFAOYSA-M 0.000 description 1
- MIBBFRQOCRYDDB-UHFFFAOYSA-N 2,3-dimethylpentan-1-ol Chemical compound CCC(C)C(C)CO MIBBFRQOCRYDDB-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- QNVRIHYSUZMSGM-LURJTMIESA-N 2-Hexanol Natural products CCCC[C@H](C)O QNVRIHYSUZMSGM-LURJTMIESA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- SGCPBVKKDRXBIB-UHFFFAOYSA-N 2-amino-2-pyridin-3-ylacetonitrile Chemical compound N#CC(N)C1=CC=CN=C1 SGCPBVKKDRXBIB-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- BIBLYXQYMWWSMT-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(3-methylpent-4-enoxy)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C=CC(C)CCOC1=NSN=C1C1=CCCN(C)C1 BIBLYXQYMWWSMT-UHFFFAOYSA-N 0.000 description 1
- YCDSLDACVAKEHN-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(4-methylhexoxy)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(C)CCCOC1=NSN=C1C1=CCCN(C)C1 YCDSLDACVAKEHN-UHFFFAOYSA-N 0.000 description 1
- XONBHEUVSAJAON-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(4-methylpentylsulfanyl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CC(C)CCCSC1=NSN=C1C1=CCCN(C)C1 XONBHEUVSAJAON-UHFFFAOYSA-N 0.000 description 1
- DWRHDCKLICPYHI-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(5-methylhexoxy)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CC(C)CCCCOC1=NSN=C1C1=CCCN(C)C1 DWRHDCKLICPYHI-UHFFFAOYSA-N 0.000 description 1
- HIHQNZIFLNAMMD-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(6,6,6-trifluorohexoxy)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1OCCCCCC(F)(F)F HIHQNZIFLNAMMD-UHFFFAOYSA-N 0.000 description 1
- FFVZARMJOYFBCJ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-[3-(5-methylthiophen-2-yl)propoxy]-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1OCCCC1=CC=C(C)S1 FFVZARMJOYFBCJ-UHFFFAOYSA-N 0.000 description 1
- GTZNCWNQHMSGSD-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-oct-7-enylsulfanyl-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1SCCCCCCC=C GTZNCWNQHMSGSD-UHFFFAOYSA-N 0.000 description 1
- SHZGEKXDAVOJTF-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-octoxy-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCCCOC1=NSN=C1C1=CCCN(C)C1 SHZGEKXDAVOJTF-UHFFFAOYSA-N 0.000 description 1
- CIGHXNHKAYSXSY-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-octylsulfanyl-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCCCSC1=NSN=C1C1=CCCN(C)C1 CIGHXNHKAYSXSY-UHFFFAOYSA-N 0.000 description 1
- CHJBRYWNHCIILD-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pent-4-enoxy-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1OCCCC=C CHJBRYWNHCIILD-UHFFFAOYSA-N 0.000 description 1
- MTHLKZIEKXRXKE-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pent-4-enylsulfanyl-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1SCCCC=C MTHLKZIEKXRXKE-UHFFFAOYSA-N 0.000 description 1
- YHSTVGGWUUGEEJ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pentoxy-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCOC1=NSN=C1C1=CCCN(C)C1 YHSTVGGWUUGEEJ-UHFFFAOYSA-N 0.000 description 1
- HOOKMYINPDKWLD-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pentylsulfanyl-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCSC1=NSN=C1C1=CCCN(C)C1 HOOKMYINPDKWLD-UHFFFAOYSA-N 0.000 description 1
- CDUMJVCGDZYWKL-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-prop-2-enoxy-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1OCC=C CDUMJVCGDZYWKL-UHFFFAOYSA-N 0.000 description 1
- KDZJAGWTPOAXRR-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-propan-2-yloxy-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CC(C)OC1=NSN=C1C1=CCCN(C)C1 KDZJAGWTPOAXRR-UHFFFAOYSA-N 0.000 description 1
- ABAUZZHICDLXNZ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-propoxy-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCOC1=NSN=C1C1=CCCN(C)C1 ABAUZZHICDLXNZ-UHFFFAOYSA-N 0.000 description 1
- XERBBZHWEILRQK-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-propylsulfanyl-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCSC1=NSN=C1C1=CCCN(C)C1 XERBBZHWEILRQK-UHFFFAOYSA-N 0.000 description 1
- DZNFBYGTWQEIHO-UHFFFAOYSA-M 3-(1-methylpyridin-1-ium-3-yl)-4-octoxy-1,2,5-thiadiazole;iodide Chemical compound [I-].CCCCCCCCOC1=NSN=C1C1=CC=C[N+](C)=C1 DZNFBYGTWQEIHO-UHFFFAOYSA-M 0.000 description 1
- CZIAAGBLEUVHOD-UHFFFAOYSA-M 3-(1-methylpyridin-1-ium-3-yl)-4-pentoxy-1,2,5-thiadiazole;iodide Chemical compound [I-].CCCCCOC1=NSN=C1C1=CC=C[N+](C)=C1 CZIAAGBLEUVHOD-UHFFFAOYSA-M 0.000 description 1
- KZIVZEGMNINNHT-UHFFFAOYSA-M 3-(1-methylpyridin-1-ium-3-yl)-4-propan-2-yloxy-1,2,5-thiadiazole;iodide Chemical compound [I-].CC(C)OC1=NSN=C1C1=CC=C[N+](C)=C1 KZIVZEGMNINNHT-UHFFFAOYSA-M 0.000 description 1
- RSXSFDUTSMLFSF-UHFFFAOYSA-N 3-(2,3-dimethylpentoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(C)C(C)COC1=NSN=C1C1=CCCN(C)C1 RSXSFDUTSMLFSF-UHFFFAOYSA-N 0.000 description 1
- OODNURDEPLJYCM-UHFFFAOYSA-N 3-(2-ethylbutylsulfanyl)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(CC)CSC1=NSN=C1C1=CCCN(C)C1 OODNURDEPLJYCM-UHFFFAOYSA-N 0.000 description 1
- PBSDSUXVSCJSFO-UHFFFAOYSA-N 3-(2-methoxyethoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.COCCOC1=NSN=C1C1=CCCN(C)C1 PBSDSUXVSCJSFO-UHFFFAOYSA-N 0.000 description 1
- OVWWWYIROJKTRA-UHFFFAOYSA-N 3-(3-methylbutoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CC(C)CCOC1=NSN=C1C1=CCCN(C)C1 OVWWWYIROJKTRA-UHFFFAOYSA-N 0.000 description 1
- ZSPTYLOMNJNZNG-UHFFFAOYSA-N 3-Buten-1-ol Chemical compound OCCC=C ZSPTYLOMNJNZNG-UHFFFAOYSA-N 0.000 description 1
- NMRPBPVERJPACX-QMMMGPOBSA-N 3-Octanol Natural products CCCCC[C@@H](O)CC NMRPBPVERJPACX-QMMMGPOBSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- MXEBUOOCRFEUOX-IPZCTEOASA-N 3-[(e)-hex-2-enoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCC\C=C\COC1=NSN=C1C1=CCCN(C)C1 MXEBUOOCRFEUOX-IPZCTEOASA-N 0.000 description 1
- ZOANUMDDLFJOQS-SNAWJCMRSA-N 3-[(e)-hex-2-enoxy]-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCC\C=C\COC1=NSN=C1C1=CC=CN=C1 ZOANUMDDLFJOQS-SNAWJCMRSA-N 0.000 description 1
- MRGCNEWHULBYIF-FXRZFVDSSA-N 3-[(e)-hex-3-enoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CC\C=C\CCOC1=NSN=C1C1=CCCN(C)C1 MRGCNEWHULBYIF-FXRZFVDSSA-N 0.000 description 1
- LKXDRTPHCOGKRP-UHFFFAOYSA-N 3-[3-(5-methylthiophen-2-yl)propoxy]-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound S1C(C)=CC=C1CCCOC1=NSN=C1C1=CC=CN=C1 LKXDRTPHCOGKRP-UHFFFAOYSA-N 0.000 description 1
- SGZFUMKNXJAQGZ-UHFFFAOYSA-N 3-but-3-enoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1OCCC=C SGZFUMKNXJAQGZ-UHFFFAOYSA-N 0.000 description 1
- KEMAWIXPTMRFCD-UHFFFAOYSA-N 3-but-3-enylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1SCCC=C KEMAWIXPTMRFCD-UHFFFAOYSA-N 0.000 description 1
- GTELBKSGWHZJFC-UHFFFAOYSA-N 3-butoxy-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCOC1=NSN=C1C1=CCCNC1 GTELBKSGWHZJFC-UHFFFAOYSA-N 0.000 description 1
- JOCWUEZEFGUDNO-UHFFFAOYSA-N 3-butylsulfanyl-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCSC1=NSN=C1C1=CCCNC1 JOCWUEZEFGUDNO-UHFFFAOYSA-N 0.000 description 1
- PJLUEUBIMKEIAX-UHFFFAOYSA-N 3-butylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCSC1=NSN=C1C1=CCCN(C)C1 PJLUEUBIMKEIAX-UHFFFAOYSA-N 0.000 description 1
- GHSRKHUQMJRXQN-UHFFFAOYSA-N 3-chloro-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1Cl GHSRKHUQMJRXQN-UHFFFAOYSA-N 0.000 description 1
- NIKIYIFUUSYDSO-UHFFFAOYSA-N 3-ethoxy-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole;hydrochloride Chemical compound Cl.CCOC1=NSN=C1C1=CCCNC1 NIKIYIFUUSYDSO-UHFFFAOYSA-N 0.000 description 1
- AIWJEMHKMBQJRN-UHFFFAOYSA-N 3-ethoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCOC1=NSN=C1C1=CCCN(C)C1 AIWJEMHKMBQJRN-UHFFFAOYSA-N 0.000 description 1
- SADMULHLCAWAOT-UHFFFAOYSA-N 3-ethylsulfanyl-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole;hydrochloride Chemical compound Cl.CCSC1=NSN=C1C1=CCCNC1 SADMULHLCAWAOT-UHFFFAOYSA-N 0.000 description 1
- MJZGKZOHTZVYON-UHFFFAOYSA-N 3-ethylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCSC1=NSN=C1C1=CCCN(C)C1 MJZGKZOHTZVYON-UHFFFAOYSA-N 0.000 description 1
- WXCVSGPFGTZUMI-UHFFFAOYSA-N 3-ethylsulfanyl-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCSC1=NSN=C1C1=CC=CN=C1 WXCVSGPFGTZUMI-UHFFFAOYSA-N 0.000 description 1
- XJNLPRMTPMMNFN-UHFFFAOYSA-N 3-heptan-2-yloxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCC(C)OC1=NSN=C1C1=CCCN(C)C1 XJNLPRMTPMMNFN-UHFFFAOYSA-N 0.000 description 1
- VNGHYKNCRVPJRP-UHFFFAOYSA-N 3-heptoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCCOC1=NSN=C1C1=CCCN(C)C1 VNGHYKNCRVPJRP-UHFFFAOYSA-N 0.000 description 1
- HCDJKWSUHBMNLM-UHFFFAOYSA-N 3-heptylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCCSC1=NSN=C1C1=CCCN(C)C1 HCDJKWSUHBMNLM-UHFFFAOYSA-N 0.000 description 1
- XDRKXIXEVXGSLU-UHFFFAOYSA-N 3-hex-4-enoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CC=CCCCOC1=NSN=C1C1=CCCN(C)C1 XDRKXIXEVXGSLU-UHFFFAOYSA-N 0.000 description 1
- GIIZDFYPLIYQJB-UHFFFAOYSA-N 3-hex-5-enoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1OCCCCC=C GIIZDFYPLIYQJB-UHFFFAOYSA-N 0.000 description 1
- DZSFEMGSWGANCQ-UHFFFAOYSA-N 3-hex-5-enylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC=C1C1=NSN=C1SCCCCC=C DZSFEMGSWGANCQ-UHFFFAOYSA-N 0.000 description 1
- ZJOUESNWCLASJP-UHFFFAOYSA-N 3-hexoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCOC1=NSN=C1C1=CCCN(C)C1 ZJOUESNWCLASJP-UHFFFAOYSA-N 0.000 description 1
- WCMFUUAZHBTPNV-UHFFFAOYSA-N 3-hexylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCSC1=NSN=C1C1=CCCN(C)C1 WCMFUUAZHBTPNV-UHFFFAOYSA-N 0.000 description 1
- KLHMNPRNRXOKHJ-UHFFFAOYSA-N 3-hexylsulfanyl-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCCCCCSC1=NSN=C1C1=CC=CN=C1 KLHMNPRNRXOKHJ-UHFFFAOYSA-N 0.000 description 1
- VTCQTYOGWYLVES-UHFFFAOYSA-N 3-methylpent-4-en-1-ol Chemical compound C=CC(C)CCO VTCQTYOGWYLVES-UHFFFAOYSA-N 0.000 description 1
- NQCSWMGUOOALOC-UHFFFAOYSA-N 3-octylsulfanyl-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCCCCCCCSC1=NSN=C1C1=CC=CN=C1 NQCSWMGUOOALOC-UHFFFAOYSA-N 0.000 description 1
- QZFZYLBJORDTLI-UHFFFAOYSA-N 3-thiophen-2-ylsulfanylpropan-1-ol Chemical compound OCCCSC1=CC=CS1 QZFZYLBJORDTLI-UHFFFAOYSA-N 0.000 description 1
- YNPVNLWKVZZBTM-UHFFFAOYSA-N 4-methylhexan-1-ol Chemical compound CCC(C)CCCO YNPVNLWKVZZBTM-UHFFFAOYSA-N 0.000 description 1
- PCWGTDULNUVNBN-UHFFFAOYSA-N 4-methylpentan-1-ol Chemical compound CC(C)CCCO PCWGTDULNUVNBN-UHFFFAOYSA-N 0.000 description 1
- ZVHAANQOQZVVFD-UHFFFAOYSA-N 5-methylhexan-1-ol Chemical compound CC(C)CCCCO ZVHAANQOQZVVFD-UHFFFAOYSA-N 0.000 description 1
- KQJFLYJMTLQJEW-UHFFFAOYSA-N 6,6,6-trifluorohexan-1-ol Chemical compound OCCCCCC(F)(F)F KQJFLYJMTLQJEW-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- PHOSWLARCIBBJZ-UHFFFAOYSA-N 6-bromohexanenitrile Chemical compound BrCCCCCC#N PHOSWLARCIBBJZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- OFGCWPHYLGEKNI-UHFFFAOYSA-N C(C(=O)O)(=O)O.C(CCCCC)SC1=NSN=C1C=1CNCCC1 Chemical compound C(C(=O)O)(=O)O.C(CCCCC)SC1=NSN=C1C=1CNCCC1 OFGCWPHYLGEKNI-UHFFFAOYSA-N 0.000 description 1
- ZSDBTJNMNRVXBI-UHFFFAOYSA-N C(C(=O)O)(=O)O.S1C(=CC=C1)SCCSC1=NSN=C1C=1CN(CCC1)C Chemical compound C(C(=O)O)(=O)O.S1C(=CC=C1)SCCSC1=NSN=C1C=1CN(CCC1)C ZSDBTJNMNRVXBI-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- URMJPDVHNMIXBK-UHFFFAOYSA-M CCCCCO[S+]1N=CN=C1C1=CC=C[N+](C)=C1.[I-] Chemical compound CCCCCO[S+]1N=CN=C1C1=CC=C[N+](C)=C1.[I-] URMJPDVHNMIXBK-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010053632 Reactive psychosis Diseases 0.000 description 1
- WGASWTPUOKTDJC-UHFFFAOYSA-N S.[Na].C(C)SC1=NSN=C1C=1C=NC=CC1 Chemical compound S.[Na].C(C)SC1=NSN=C1C=1C=NC=CC1 WGASWTPUOKTDJC-UHFFFAOYSA-N 0.000 description 1
- VSPJRJBVKIAQBC-UHFFFAOYSA-N S.[Na].C(CCCCC)SC1=NSN=C1C=1C=NC=CC1 Chemical compound S.[Na].C(CCCCC)SC1=NSN=C1C=1C=NC=CC1 VSPJRJBVKIAQBC-UHFFFAOYSA-N 0.000 description 1
- HAFFKOJGYPTWKF-UHFFFAOYSA-N S.[Na].C(CCCCCCC)SC1=NSN=C1C=1C=NC=CC1 Chemical compound S.[Na].C(CCCCCCC)SC1=NSN=C1C=1C=NC=CC1 HAFFKOJGYPTWKF-UHFFFAOYSA-N 0.000 description 1
- 208000030988 Schizoid Personality disease Diseases 0.000 description 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 208000024453 abnormal involuntary movement Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- PXJJSXABGXMUSU-UHFFFAOYSA-N disulfur dichloride Chemical compound ClSSCl PXJJSXABGXMUSU-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N n-butyl methyl ketone Natural products CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- ZHWBHORPAPSAKX-UHFFFAOYSA-N oxalic acid;3-pentylsulfanyl-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound OC(=O)C(O)=O.CCCCCSC1=NSN=C1C1=CCCNC1 ZHWBHORPAPSAKX-UHFFFAOYSA-N 0.000 description 1
- KNAYMUKMSAFJFG-UHFFFAOYSA-N oxalic acid;3-propylsulfanyl-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound OC(=O)C(O)=O.CCCSC1=NSN=C1C1=CCCNC1 KNAYMUKMSAFJFG-UHFFFAOYSA-N 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- LQAVWYMTUMSFBE-UHFFFAOYSA-N pent-4-en-1-ol Chemical compound OCCCC=C LQAVWYMTUMSFBE-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- ASUAYTHWZCLXAN-UHFFFAOYSA-N prenol Chemical compound CC(C)=CCO ASUAYTHWZCLXAN-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- WRVHPSSSTBDGRK-UHFFFAOYSA-N sodium;sulfane;hydrate Chemical compound O.[Na].S WRVHPSSSTBDGRK-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- JOLJIIDDOBNFHW-UHFFFAOYSA-N xanomeline Chemical compound CCCCCCOC1=NSN=C1C1=CCCN(C)C1 JOLJIIDDOBNFHW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10930093A | 1993-08-19 | 1993-08-19 | |
| PCT/DK1994/000305 WO1995005174A1 (en) | 1993-08-19 | 1994-08-15 | Antipsychotic method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO960619D0 NO960619D0 (no) | 1996-02-16 |
| NO960619L NO960619L (no) | 1996-04-18 |
| NO312706B1 true NO312706B1 (no) | 2002-06-24 |
Family
ID=22326932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19960619A NO312706B1 (no) | 1993-08-19 | 1996-02-16 | Anvendelse av tiadiazolforbindelser til fremstilling av farmasöytiske preparater for behandling av schizofreni ogschizofreniforme sykdommer |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0734259B1 (de) |
| JP (1) | JP3126736B2 (de) |
| KR (1) | KR100360575B1 (de) |
| CN (1) | CN1087936C (de) |
| AT (1) | ATE218864T1 (de) |
| AU (1) | AU701292B2 (de) |
| CA (1) | CA2169839C (de) |
| CZ (1) | CZ285030B6 (de) |
| DE (1) | DE69430816T2 (de) |
| DK (1) | DK0734259T3 (de) |
| ES (1) | ES2177581T3 (de) |
| FI (2) | FI960747A (de) |
| HU (1) | HU221729B1 (de) |
| IL (1) | IL110708A (de) |
| NO (1) | NO312706B1 (de) |
| NZ (2) | NZ336597A (de) |
| PT (1) | PT734259E (de) |
| RU (1) | RU2191580C2 (de) |
| SG (1) | SG55071A1 (de) |
| TW (1) | TW442284B (de) |
| UA (1) | UA63876C2 (de) |
| WO (1) | WO1995005174A1 (de) |
| ZA (1) | ZA946324B (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605908A (en) * | 1994-10-24 | 1997-02-25 | Eli Lilly And Company | Heterocyclic compounds and their use |
| US5998404A (en) * | 1994-10-24 | 1999-12-07 | Eli Lilly And Company | Heterocyclic compounds and their use |
| US5665745A (en) * | 1994-10-24 | 1997-09-09 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
| US5574028A (en) * | 1994-10-31 | 1996-11-12 | Eli Lilly And Company | Method for treating anxiety |
| US5726193A (en) * | 1994-10-31 | 1998-03-10 | Eli Lilly And Company | Method for treating anxiety |
| EP0709094B1 (de) * | 1994-10-31 | 2000-04-05 | Eli Lilly And Company | Tetrahydropyridin Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen |
| US5488056A (en) * | 1994-10-31 | 1996-01-30 | Eli Lilly And Company | Method for treating anxiety |
| US5565475A (en) * | 1994-11-08 | 1996-10-15 | Muhlhauser; Mark A. | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives |
| US5763457A (en) * | 1995-11-13 | 1998-06-09 | Eli Lilly And Company | Method for treating anxiety |
| US5852037A (en) * | 1995-11-13 | 1998-12-22 | Eli Lilly And Company | Method for treating anxiety |
| EP0821959A3 (de) * | 1996-08-01 | 1998-09-16 | Eli Lilly And Company | Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin zur Behandlung von Nikotin-Entzug |
| EP0821957A3 (de) * | 1996-08-01 | 1998-04-22 | Eli Lilly And Company | Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von Drogenmissbrauch |
| PT821955E (pt) * | 1996-08-01 | 2002-07-31 | Lilly Co Eli | Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para o tratamento da doenca bipolar |
| US6043258A (en) * | 1996-08-01 | 2000-03-28 | Eli Lilly And Company | Method for treating disruptive behavior disorders with xanomeline |
| EP0821956A1 (de) * | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Verfahren zur Behandlung disruptiver Verhaltensstörungen |
| US6090829A (en) * | 1996-08-01 | 2000-07-18 | Eli Lilly And Company | Method for treating excessive aggression |
| EP0821954A1 (de) * | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Verfahren zur Behandlung von geistiger Zurückgebliebenheit |
| EP0821958A3 (de) * | 1996-08-01 | 1998-07-08 | Eli Lilly And Company | Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von übermässiger Streitsucht |
| US6117890A (en) * | 1996-08-01 | 2000-09-12 | Eli Lilly And Company | Method for treating bipolar disorder |
| ES2227836T3 (es) * | 1997-05-29 | 2005-04-01 | H. Lundbeck A/S | Tratamiento de esquizofrenia y psicosis. |
| US6034108A (en) * | 1997-07-28 | 2000-03-07 | Eli Lilly And Company | Method for treating mental retardation |
| ES2742728T3 (es) | 2009-07-22 | 2020-02-17 | PureTech Health LLC | Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico |
| AU2019346626B2 (en) | 2018-09-28 | 2022-06-02 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
| WO2021097427A1 (en) | 2019-11-15 | 2021-05-20 | Karuna Therapeutics, Inc. | Xanomeline derivatives and methods for treating neurological disorders |
| CN115974863A (zh) * | 2021-10-14 | 2023-04-18 | 南京迈诺威医药科技有限公司 | 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ225999A (en) * | 1987-09-10 | 1992-04-28 | Merck Sharp & Dohme | Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions |
| US5043345A (en) * | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DK198490D0 (da) * | 1990-08-21 | 1990-08-21 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
| DK198390D0 (da) * | 1990-08-21 | 1990-08-21 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
-
1994
- 1994-08-15 CZ CZ96426A patent/CZ285030B6/cs not_active IP Right Cessation
- 1994-08-15 KR KR1019960700806A patent/KR100360575B1/ko not_active IP Right Cessation
- 1994-08-15 DK DK94924708T patent/DK0734259T3/da active
- 1994-08-15 WO PCT/DK1994/000305 patent/WO1995005174A1/en active Application Filing
- 1994-08-15 HU HU9600364A patent/HU221729B1/hu not_active IP Right Cessation
- 1994-08-15 AU AU74902/94A patent/AU701292B2/en not_active Ceased
- 1994-08-15 CN CN94193733A patent/CN1087936C/zh not_active Expired - Fee Related
- 1994-08-15 UA UA96020584A patent/UA63876C2/uk unknown
- 1994-08-15 EP EP94924708A patent/EP0734259B1/de not_active Expired - Lifetime
- 1994-08-15 SG SG1996004738A patent/SG55071A1/en unknown
- 1994-08-15 NZ NZ336597A patent/NZ336597A/en unknown
- 1994-08-15 NZ NZ271311A patent/NZ271311A/en not_active IP Right Cessation
- 1994-08-15 PT PT94924708T patent/PT734259E/pt unknown
- 1994-08-15 JP JP07506691A patent/JP3126736B2/ja not_active Expired - Lifetime
- 1994-08-15 CA CA002169839A patent/CA2169839C/en not_active Expired - Fee Related
- 1994-08-15 RU RU96105388/14A patent/RU2191580C2/ru not_active IP Right Cessation
- 1994-08-15 ES ES94924708T patent/ES2177581T3/es not_active Expired - Lifetime
- 1994-08-15 AT AT94924708T patent/ATE218864T1/de not_active IP Right Cessation
- 1994-08-15 DE DE69430816T patent/DE69430816T2/de not_active Expired - Lifetime
- 1994-08-18 IL IL11070894A patent/IL110708A/en not_active IP Right Cessation
- 1994-08-19 ZA ZA946324A patent/ZA946324B/xx unknown
-
1995
- 1995-02-15 TW TW084101387A patent/TW442284B/zh not_active IP Right Cessation
-
1996
- 1996-02-16 NO NO19960619A patent/NO312706B1/no not_active IP Right Cessation
- 1996-02-19 FI FI960747A patent/FI960747A/fi not_active Application Discontinuation
-
2005
- 2005-04-29 FI FI20050461A patent/FI20050461A/fi not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO312706B1 (no) | Anvendelse av tiadiazolforbindelser til fremstilling av farmasöytiske preparater for behandling av schizofreni ogschizofreniforme sykdommer | |
| JP5686596B2 (ja) | 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子 | |
| US5968926A (en) | Antipsychotic method | |
| US5744489A (en) | Method of treating gastrointestinal motility disorders | |
| US5750541A (en) | Method of treating schizophrenia | |
| US5565475A (en) | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives | |
| AU697529C (en) | Antipsychotic method | |
| US5545638A (en) | Method of treating gastrointestinal motility disorders | |
| US5663182A (en) | Antipsychotic method | |
| EP0735869A1 (de) | Verfahren zur behandlung von gastrointestinalen rotilitätsstörungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO |
|
| MM1K | Lapsed by not paying the annual fees |